Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.4474
- Book/Share 0.8269
- PB 231.7201
- Debt/Equity 49.2176
- CurrentRatio 0.7602
- ROIC 0.1793
- MktCap 328744704000.0
- FreeCF/Share 8.7019
- PFCF 21.3679
- PE 78.4368
- Debt/Assets 0.5133
- DivYield 0.0343
- ROE 0.9559
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging that AbbVie violated the Illinois Genetic Information Privacy Act ("GIPA"). In Henry v.
Read More
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
Read More
Here's How to Play AbbVie Stock as it Enters the Obesity Space
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Read More
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
Published: March 03, 2025 by: Benzinga
Sentiment: Positive
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
Read More
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Published: March 03, 2025 by: Investopedia
Sentiment: Neutral
AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
Read More
Final Trades: Taiwan Semi, Abbvie, Tradeweb Markets and the IYH
Published: March 03, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
Read More
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission,† were met1 GCA is an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2 NORTH CHICAGO, Ill. , Feb. 28, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) …
Read More
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Published: February 27, 2025 by: The Motley Fool
Sentiment: Positive
Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines.
Read More
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025.
Read More
Why AbbVie Remains A Strong Buy For Long-Term Investors
Published: February 23, 2025 by: Seeking Alpha
Sentiment: Positive
Why AbbVie Remains A Strong Buy For Long-Term Investors
Read More
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
Published: February 20, 2025 by: The Motley Fool
Sentiment: Positive
Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ability to generate steady revenue growth and strong free cash flows across different market cycles.
Read More
AbbVie Appears Ready To Move Higher
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq, shows robust growth. AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration.
Read More
AbbVie: An Undervalued Dividend Aristocrat
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets like immunology, neuroscience, and aesthetics, ensuring resilience and a wide moat. AbbVie consistently increases dividends, supported by solid financial health, robust cash reserves, and moderate leverage, reinforcing its attractiveness to investors.
Read More
AbbVie Just Paid Investors: Here's How Much They Received
Published: February 14, 2025 by: 24/7 Wall Street
Sentiment: Positive
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.
Read More
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A.
Read More
All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend stocks. Focused on wide-moat businesses, I prioritize quality and long-term growth over yield. My portfolio has outperformed the S&P 500, and I'm confident in its future. I expect a rotation to value stocks, and I'll keep sharing insights to grow together.
Read More
AbbVie Declares Quarterly Dividend
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Read More
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass.
Read More
3 Fabulous Dividend Stocks to Buy in February
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert A. Michael CPA
- Employees 55000